Glider | $4,000,000 | (Apr 18, 2025)
Graze Social | $1,000,000 | (Apr 18, 2025)
Nyobolt | $30,000,000 | (Apr 18, 2025)
Ampersand Biomedicines
United States
- Boston, Massachusetts
- 26/03/2025
- Series B
- $65,000,000
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.
- Industry Biotechnology Research
- Website https://www.ampersand.bio/
- LinkedIn https://www.linkedin.com/company/ampersand-biomedicines/
Related People
Jason GardnerFounder
United States -
Cambridge, Massachusetts
Jason is CEO-Partner, Flagship Pioneering and CEO, Ampersand Biomedicines, which is advancing a powerful platform for the creation of smarter medicines. He was previously, CEO, President and Cofounder of Magenta Therapeutics. He has held leadership roles in pharma and biotech over 20 years, where he established and ran the GSK R&D Satellite in Boston. He also created and led the Regenerative Medicine Discovery Performance Unit, a global team across R&D that established the stem cell gene therapy programs in pharma and ran multiple collaborations. Jason joined GSK in 2005 following eight years in the biotech arena to become a member of the lapatinib clinical team that led to the successful new drug application file for Tykerb in breast cancer in 2007. He then joined the CEEDD, later leading Research and Alliance Management, where new alliances were established with multiple biotech companies. Jason was educated at Cambridge University where he received B.A. and M.A. degrees in Natural Sciences. He completed his Ph.D. at Oxford University and was a Research Fellow in Medicine at Harvard University.
Booked it | $3,316,375 | (Apr 18, 2025)
FOTENIX | $2,785,755 | (Apr 18, 2025)
Exaforce Inc. | $75,000,000 | (Apr 18, 2025)
Pillar Security | $9,000,000 | (Apr 18, 2025)
Cy4Data Labs | $10,000,000 | (Apr 18, 2025)
Meadow | $14,000,000 | (Apr 18, 2025)
Trellis Health | $1,800,000 | (Apr 18, 2025)
RISA | $3,500,000 | (Apr 18, 2025)
Vizzy | B Corp™ | $4,841,908 | (Apr 18, 2025)
Assort Health | $26,000,000 | (Apr 18, 2025)